Expanded deal focuses on Synaffix’s GlycoConnect™ site-specific ADC bioconjugation technology and adds license options for six new programs to existing dealMersana currently developing two programs based on GlycoConnect™ site-specific ADC bioconjugation technology...
Confo will work together with Regeneron to apply its GPCR drug discovery platform to enable functional antibody discovery Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron...
First four dose escalation levels completed showing excellent tolerability for CTL-002 as monotherapy and in combination with PD-1Preliminary pharmacodynamic analyses at early dose levels indicate CTL-002-mediated selective T cell shift into the tumor...
Naarden, The Netherlands, 16 November 2021 – NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, today announces the presentation of new interim data from the Phase 2b...
Amsterdam, The Netherlands, 02 November 2021 – BioGeneration Ventures (“BGV”), a leading early-stage VC in European biopharma today announces that Dunad Therapeutics (“Dunad”), a biopharmaceutical company focusing on the development of protein degradation...
AMSTERDAM, NETHERLANDS – 28 October 2021 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index today announces that...
